Asia Pacific Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Asia Pacific recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Asia Pacific recombinant protein therapeutics cdmo market highlights
- The Asia Pacific recombinant protein therapeutics cdmo market generated a revenue of USD 5,426.6 million in 2023.
- The market is expected to grow at a CAGR of 14.3% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 5,426.6 million |
| Market revenue in 2030 | USD 13,871.8 million |
| Growth rate | 14.3% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 26.0% of the global recombinant protein therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,871.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.45% in 2023. Horizon Databook has segmented the Asia Pacific recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The regional growth can be attributed to various amendments made by regulatory organizations to change clinical trial evaluation standards according to global requirements as well as various major players investing in Asia Pacific. Furthermore, the changing business model of MNC outsourcing and R&D activities is expected to propel recombinant protein therapeutics CDMO demand in the Asia Pacific owing to the cost-efficiency offered by CDMO in countries such as India and China.
These countries are expected to witness lucrative growth in the recombinant protein therapeutics CDMO market, whereas countries such as South Korea, Australia, and Thailand are also expected to witness steady growth over the forecast period. The establishment of several CDMOs across the Asia Pacific region has also strengthened innovation in therapies in the region.
Emerging economies of Asian countries are contributing to growth of this region with ongoing studies in drug discovery, collaborations, and government initiatives. Furthermore, the growing need for recombinant protein therapeutics production in pharmaceutical and biopharmaceutical companies has led to increased spending by pharmaceutical companies to boost therapy development, which is likely to fuel growth of the recombinant protein therapeutics CDMO market in this region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific recombinant protein therapeutics cdmo market size, by country, 2018-2030 (US$M)
Asia Pacific Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
